Report #2825420

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 74 yrs
State: TX
Recovered: Unknown
Vaccinated: Jan 18, 2025
Onset: Jan 18, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	3	BP74J	—

Symptoms (1)

Extra dose administered

Symptom narrative

3rd dose administered; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 74-year-old female patient who received Herpes zoster (Shingrix) (batch number BP74J, expiry date 15-NOV-2026) for prophylaxis. Previously administered products included Shingrix (1st dose on 24th Dec, 2019), Shingrix (2nd dose on 27th Feb, 2020) and Zostavax. On 18-JAN-2025, the patient received the 3rd dose of Shingrix. On 18-JAN-2025, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: 3rd dose administered). The outcome of the extra dose administered was unknown. Additional Information: GSK receipt date: 22-JAN-2025 Other HCP reported that a patient got a 3rd dose of Shingrix. According to reporter on 24th Dec, 2019, the patient received the 1st dose of Shingrix. Then, on 27th Feb, 2020 the patient received the 2nd dose of Shingrix. After that, on 18th Jan, 2025 the patient received the 3rd dose of Shingrix, which led to extra dose administered.